Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)

Peking University People's Hospital131 enrolled

Overview

The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

131

Conditions

Central Serous Chorioretinopathy

Interventions

PDTPROCEDURE

30% or 50% verteporfin dose PDT was given to patients with CSC

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with CSC * patients signed the ICF * patients with course of CSC less than 6 months * patients did not undertake any treatment for CSC Exclusion Criteria: * patients with porphyria * patients allergic to verteporfin * pregnant or nursing women * poor patients compliance * sever liver dysfunction * dioptric media opacities which make it difficult to exam fundus

Locations (1)

People's Hospital of Peking University

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Change from baseline in BCVA

Time frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

Secondary Outcomes

Leakage at RPE level in FA

Time frame: 1 week

Change from baseline in central retinal thickness

Time frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

The incidence rate of adverse event

Time frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.